<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7438404\results\search\testTrace\results.xml">
  <result pre="compounds as potential SARS-CoV-2 drug candidates. antivirals coronaviruses COVID-19 SARS-CoV-2" exact="treatment" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Coronaviruses (CoVs)"/>
  <result pre="can cause mild to severe symptoms related to upper respiratory" exact="infection" post="such as fever, cough, dyspnea, pneumonia, and acute respiratory"/>
  <result pre="2020), evidencing the mandatory need for further research encompassing antiviral" exact="treatment" post="against CoVs, which has somehow, until recently, been relatively"/>
  <result pre="viable on surfaces for several days, increasing the probability of" exact="infection" post="by third parties (van Doremalen et al., 2020). Recently,"/>
  <result pre="with a broad-spectrum effect (human and animal CoVs); protected against" exact="infection" post="and improved survival in animal assay (Balb/c) Oâ€™Keefe et"/>
  <result pre="suggesting that NAAE might be a candidate for treating SARS" exact="infection" post="by impairing viral attachment via interference with ACE2 (Huentelman"/>
  <result pre="In another study, GRFT inhibited the early stages of MERS-CoV" exact="infection" post="in HEK-293T cells (Millet et al., 2016). Furthermore, GRFT"/>
  <result pre="in SARS-CoV-infected mice and protected the Balb/c female mice against" exact="infection" post="by binding with S protein (Oâ€™Keefe et al., 2010)."/>
  <result pre="the hexapeptide Tyr-Lys-Tyr-Arg-Tyr-Leu at 14 mM inhibited SARS-CoV and HCoV-NL63" exact="infection" post="in Vero cells without triggering cytotoxicity (Struck et al.,"/>
  <result pre="(Kim et al., 2013). Moreover, the authors described that concomitant" exact="treatment" post="with these compounds can improve the antiviral effect against"/>
  <result pre="is a synthetic nucleoside analog of guanosine used for the" exact="treatment" post="of patients chronically infected by the hepatitis C virus"/>
  <result pre="et al., 2017). Moreover, ribavirin showed good results for the" exact="treatment" post="of critical MERS-CoV patients (Al-Tawfiq et al., 2014), and"/>
  <result pre="critical MERS-CoV patients (Al-Tawfiq et al., 2014), and the combined" exact="treatment" post="of ribavirin with type I Interferons (IFN-I) in primate"/>
  <result pre="al., 2013b). Although ribavirin has been given as part of" exact="treatment" post="regimens for SARS and MERS patients, meta-analyses of cases"/>
  <result pre="report the activities of Niclosamide, a drug used in antihelminthic" exact="treatment" post="(Katz, 1977). Niclosamide presented antiviral activity on post-entry steps"/>
  <result pre="1977). Niclosamide presented antiviral activity on post-entry steps of SARS-CoV" exact="infection" post="in Vero cells, with an EC50 of 1â€&quot;3 Î¼M"/>
  <result pre="immune responses that are important for preventing or limiting viral" exact="infection" post="(Barnard et al., 2006). Bananins, on the other hand,"/>
  <result pre="assessed TP29 activity in MHV infected mice and demonstrated that" exact="treatment" post="improved survival, decreased viral load in liver, and induced"/>
  <result pre="Approach to CoV Treatment Targeting the host process during viral" exact="infection" post="figures as a promising alternative for drug development and"/>
  <result pre="2019). Nitazoxanide is a broad-spectrum antiviral agent exploited for the" exact="treatment" post="of, for instance, influenza A and B viruses, as"/>
  <result pre="2013) and have been described as promising candidates for the" exact="treatment" post="of hepatitis B virus (HBV), HCV, HIV, and human"/>
  <result pre="(siRNAs) were described as being effective for in vitro antiviral" exact="treatment" post="of FIPV, a type of FCoV (McDonagh et al.,"/>
  <result pre="70% (Ã…kerstrÃ¶m et al., 2007). The different authors propose that" exact="treatment" post="with siRNAs can improve treatment-resistance among viruses and that"/>
  <result pre="the current knowledge on the most promising candidates for the" exact="treatment" post="of COVID-19. Data for these drugs are summarized in"/>
  <result pre="(NCT04292899), which have been conducted based on the first reported" exact="treatment" post="of COVID-19 with Remdesivir in Washington, United States (Holshue"/>
  <result pre="al., 2009). Lopinavir demonstrated antiviral activities, protecting cells from MERS-CoV" exact="infection" post="(EC50 of 8 Î¼M) and reducing viral loads in"/>
  <result pre="and the period of hospitalization, representing a possibility for the" exact="treatment" post="of SARS-CoV-2 (Chu et al., 2004). Cao and collaborators"/>
  <result pre="vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation). Additionally, the" exact="treatment" post="generated relevant adverse effects in some of the patients"/>
  <result pre="COVID-19 patients alleviated symptoms and decreased the durations of viral" exact="infection" post="and hospital stay (Hung et al., 2020). This might"/>
  <result pre="properties (Samuel, 2001). Therefore, they are commonly employed in the" exact="treatment" post="of several diseases such as Hepatitis C (Kobayashi et"/>
  <result pre="et al., 2015) and is therefore capitalized on in the" exact="treatment" post="for multiple sclerosis patients (Axtell et al., 2010). Due"/>
  <result pre="NCT043274011, but considering the preliminary results, the WHO suggested that" exact="treatment" post="with dexamethasone may be applied during the third phase"/>
  <result pre="is Umifenovir, a licensed antiviral exploited for the prophylaxis and" exact="treatment" post="of influenza viruses (Arbidol), which demonstrated good pharmacokinetics when"/>
  <result pre="observational study with 81 patients with moderate to severe SARS-CoV-2" exact="infection" post="(Lian et al., 2020) that demonstrated that Umifenovir neither"/>
  <result pre="IL-6 receptor antagonist approved by the US FDA for the" exact="treatment" post="of severe CRS (Grupp et al., 2013) and figures"/>
  <result pre="cytokine storm caused by SARS-CoV-2 (Zhang et al., 2020b). The" exact="treatment" post="of patients with severe COVID-19 with Tocilizumab presented no"/>
  <result pre="improved the clinical outcome and appeared to be an effective" exact="treatment" post="for reducing mortality (Xu et al., 2020). Another study"/>
  <result pre="reducing mortality (Xu et al., 2020). Another study employing the" exact="treatment" post="of COVID-19 patients with Tocilizumab for 14 days reinforced"/>
  <result pre="patients with Tocilizumab for 14 days reinforced these observations. The" exact="treatment" post="was observed to cause an effective decrease in inflammatory"/>
  <result pre="2017). Chloroquine was described as an entry inhibitor of SARS-CoV" exact="infection" post="in Vero cells and prevented cell-to-cell spread of the"/>
  <result pre="monocytes. Additionally, an in vivo study in cats demonstrated that" exact="treatment" post="with chloroquine improved the clinical score of treated groups"/>
  <result pre="malaria for both adults and children are considered for the" exact="treatment" post="(Smith, 2020). Recently, the WHO stopped the hydroxychloroquine arm"/>
  <result pre="of these drugs for COVID-19 requires further investigation. An alternative" exact="treatment" post="for COVID-19 is the utilization of convalescent plasma (CP)"/>
  <result pre="of convalescent plasma (CP) (Chen L. et al., 2020). This" exact="treatment" post="refers to plasma therapy based on plasma or plasma"/>
  <result pre="is, in its turn, transfused into individuals with acute SARS-CoV-2" exact="infection" post="(Garraud, 2017; Cao and Shi, 2020). Even though the"/>
  <result pre="is not fully understood, it presented great results in the" exact="treatment" post="of patients with SARS during the SARS-CoV outbreak in"/>
  <result pre="guarantee the effectiveness of CP therapy: Ab titers and the" exact="treatment" post="time point. Firstly, taking into consideration previous knowledge from"/>
  <result pre="decrease 4 months after the disease. Secondly, patients receiving CP" exact="treatment" post="prior to 14 days post-infection responded better than patients"/>
  <result pre="anti-CoVs activities and that could be further exploited for the" exact="treatment" post="of human and animal CoVs. Furthermore, we described ongoing"/>
  <result pre="development. Also, the exploitation of in silico studies for drug" exact="screening" post="to seek specific targets, as well as for a"/>
  <result pre="described above, these compounds were capable of significantly impairing CoV" exact="infection" post="in cell cultures and might enable important progress into"/>
  <result pre="in cell cultures and might enable important progress into the" exact="treatment" post="of described CoVs as well as viruses that might"/>
  <result pre="C57BL/6, to evaluate the antiviral effect of compounds in CoV" exact="infection" post="(Cinatl et al., 2003; Saijo et al., 2005; Barnard"/>
  <result pre="classified to different biological safety levels, representing a risk of" exact="infection" post="to scientists (Bayot and King, 2020; CDC, 2020b). Additionally,"/>
  <result pre="The development of refined and secure protocols to study SARS-CoV-2" exact="infection" post="and its treatment options is required. Bearing in mind"/>
  <result pre="refined and secure protocols to study SARS-CoV-2 infection and its" exact="treatment" post="options is required. Bearing in mind the obstacles cited"/>
  <result pre="Saracatinib, Tizoxanide, Nitazoxanide, Niclosamide, and Ribavirin. These compounds abrogated CoV" exact="infection" post="in vitro and in vivo and improved the symptoms"/>
  <result pre="Lopinavir and Ritonavir, and Umifenovir are drugs employed for the" exact="treatment" post="of other viral infections such as EBOV and SARS-CoV,"/>
  <result pre="other drugs, collaborating to control immune response against the viral" exact="infection" post="(Table 2). On the other hand, corticosteroids, such as"/>
  <result pre="effect in severe cases cannot be rejected as a possible" exact="treatment" post="in mild to severe cases. When these aspects are"/>
  <result pre="limited knowledge about its physiopathology. Finally, the development of new" exact="treatment" post="options is critical, and efforts have been focused on"/>
  <result pre="with minimal toxicity. Another point to be considered in CoV" exact="treatment" post="is that RNA viruses are known to have high"/>
  <result pre="information on the resistance associated with these drugs in the" exact="treatment" post="of viral infections. Conclusion The spread of SARS-CoV-2 worldwide"/>
  <result pre="an efficacious treatment. In addition, and despite the urgency of" exact="treatment" post="protocols, it is important to point out the striking"/>
  <result pre="AlattarR.IbrahimT. B. H.ShaarS. H.AbdallaS.ShukriK.DaghfalJ. N.et al. (2020). Tocilizumab for the" exact="treatment" post="of severe coronavirus disease 2019.J. Med. Virol. Online ahead"/>
  <result pre="acidification by chloroquine analogs as a promising strategy for the" exact="treatment" post="of emerging viral diseases.Pharmacol. Res. Perspect.51â€&quot;13. 10.1002/prp2.29328596841 Al-TawfiqJ. A.MomattinH.DibJ.MemishZ."/>
  <result pre="(2015). Treatment with lopinavir/ritonavir or interferon-Î²1b improves outcome of MERS-CoV" exact="infection" post="in a nonhuman primate model of common marmoset.J. Infect."/>
  <result pre="10.1002/jmv.2568131967327 ChenJ.LiuD.LiuL.LiuP.XuQ.XiaL.et al. (2020). [A pilot study of hydroxychloroquine in" exact="treatment" post="of patients with moderate COVID-19].Zhejiang Xue Xue Bao Yi"/>
  <result pre="Dis.2444â€&quot;46. 10.1007/s10096-004-1271-915616839 ChihrinS.LoutfyM. R. (2005). Overview of antiviral and anti-inflammatory" exact="treatment" post="for severe acute respi ratory syndrome.Expert Rev. Anti Infect."/>
  <result pre="L.ChanK. H.ChanK. S.et al. (2004). Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings.Thorax59252â€&quot;256. 10.1136/thorax.2003.01265814985565 ChuH.ChanJ."/>
  <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse model.Virus Res.2287â€&quot;13. 10.1016/j.virusres.2016.11.01127840112 de WildeA. H.JochmansD.PosthumaC."/>
  <result pre="10.1099/vir.0.034983-021752960 De WitE.FeldmannF.CroninJ.JordanR.OkumuraA.ThomasT.et al. (2020). Prophylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infection.Proc. Natl."/>
  <result pre="GaoJ.TianZ.YangX. (2020). Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies.Biosci. Trends1472â€&quot;73. 10.5582/BST.2020.0104732074550"/>
  <result pre="10.1016/j.transci.2016.12.01428094110 GautretP.LagierJ.-C.ParolaP.HoangV. T.MeddebL.MailheM.et al. (2020). Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial.Int."/>
  <result pre="HaynesL. M.CaidiH.RaduG. U.MiaoC.HarcourtJ. L.TrippR. A.et al. (2009). Therapeutic monoclonal antibody" exact="treatment" post="targeting respiratory syncytial virus (RSV) G protein mediates viral"/>
  <result pre="protein mediates viral clearance and reduces the pathogenesis of RSV" exact="infection" post="in BALB/c mice.J. Infect. Dis.200439â€&quot;447. 10.1086/60010819545210 HensleyL. E.FritzE. A.JahrlingP."/>
  <result pre="Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the" exact="treatment" post="of patients admitted to hospital with COVID-19: an open-label,"/>
  <result pre="respiratory syndrome coronavirus main protease discovered by a combination of" exact="screening" post="and docking methods.J. Med. Chem.486832â€&quot;6842. 10.1021/jm050178216250642 KahnJ. S.McIntoshK. (2005)."/>
  <result pre="influenza H5N1 viruses.Peptides321518â€&quot;1525. 10.1016/j.peptides.2011.05.01521620914 LiX.GengM.PengY.MengL.LuS. (2020). Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19.J. Pharm. Anal.10102â€&quot;108. 10.1016/j.jpha.2020.03.00132282863 LianN.XieH.LinS.HuangJ.ZhaoJ.LinQ. (2020). Umifenovir treatment"/>
  <result pre="and diagnosis of COVID-19.J. Pharm. Anal.10102â€&quot;108. 10.1016/j.jpha.2020.03.00132282863 LianN.XieH.LinS.HuangJ.ZhaoJ.LinQ. (2020). Umifenovir" exact="treatment" post="is not associated with improved outcomes in patients with"/>
  <result pre="of the HR2 of the S protein neutralize in vitro" exact="infection" post="of severe acute respiratory syndrome coronavirus.J. Virol.80941â€&quot;950. 10.1128/JVI.80.2.941-950.200616378996 LipinskiC."/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro.Cell Discov.61â€&quot;4. 10.1038/s41421-020-0156-031934347 LuG.WangQ.GaoG. F. (2015). Bat-to-human: spike"/>
  <result pre="antiviral monoclonal antibody therapeutics.Nat. Biotechnol.251421â€&quot;1434. 10.1038/nbt136318066039 MatsuyamaS.NaoN.ShiratoK.KawaseM.SaitoS.TakayamaI.et al. (2020). Enhanced" exact="isolation" post="of SARS-CoV-2 by TMPRSS2-expressing cells.Proc. Natl. Acad. Sci. U.S.A.1177001â€&quot;7003."/>
  <result pre="N.DanneelsA.PalmerK. E.WhittakerG. R.et al. (2016). Middle East respiratory syndrome coronavirus" exact="infection" post="is inhibited by griffithsin.Antiviral Res.1331â€&quot;8. 10.1016/j.antiviral.2016.07.01127424494 MillsA. M.NelsonM.JayaweeraD.RuxrungthamK.CassettiI.GirardP.-M.et al."/>
  <result pre="and other intracellular pathogens and suggests a new strategy for" exact="treatment" post="of diseases caused by intracellular parasites.Med. Hypotheses62354â€&quot;357. 10.1016/j.mehy.2003.12.00414975502 PayneS."/>
  <result pre="PettittJ.ZeitlinL.KimD. H.WorkingC.JohnsonJ. C.BohorovO.et al. (2013). Therapeutic intervention of ebola virus" exact="infection" post="in rhesus macaques with the MB-003 monoclonal antibody cocktail.Sci."/>
  <result pre="PyrcK.BoschB. J.BerkhoutB.JebbinkM. F.DijkmanR.RottierP.et al. (2006). Inhibition of human coronavirus NL63" exact="infection" post="at early stages of the replication cycle.Antimicrob. Agents Chemother.502000â€&quot;2008."/>
  <result pre="Springer), 597â€&quot;600. 10.1007/978-0-387-33012-9_108 RoquesP.ThibervilleS.-D.Dupuis-MaguiragaL.LumF.-M.LabadieK.MartinonF.et al. (2018). Paradoxical effect of chloroquine" exact="treatment" post="in enhancing chikungunya virus infection.Viruses10:268. 10.3390/v1005026829772762 RossignolJ.-F. (2014). Nitazoxanide:"/>
  <result pre="10.1016/j.antiviral.2014.07.01425108173 RossignolJ.-F. (2016). Nitazoxanide, a new drug candidate for the" exact="treatment" post="of Middle East respiratory syndrome coronavirus.J. Infect. Public Health9227â€&quot;230."/>
  <result pre="Res.66159â€&quot;163. 10.1016/j.antiviral.2005.01.00315911031 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020). Type 1 interferons as a potential" exact="treatment" post="against COVID-19.Antiviral Res.178:104791. 10.1016/j.antiviral.2020.10479132275914 SamuelC. E. (2001). Antiviral Actions"/>
  <result pre="L blocks severe acute respiratory syndrome and ebola pseudotype virus" exact="infection" post="into human embryonic kidney 293T cells.Mol. Pharmacol.78319â€&quot;324. 10.1124/mol.110.06426120466822 ShahP."/>
  <result pre="Med.6:eabb5883. 10.1126/scitranslmed.abb588332253226 ShenL.YangY.YeF.LiuG.DesforgesM.TalbotP. J.et al. (2016). Safe and sensitive antiviral" exact="screening" post="platform based on recombinant human Coronavirus OC43 expressing the"/>
  <result pre="TakanoT.KatohY.DokiT.HohdatsuT. (2013). Effect of chloroquine on feline infectious peritonitis virus" exact="infection" post="in vitro and in vivo.Antiviral Res.99100â€&quot;107. 10.1016/j.antiviral.2013.04.01623648708 TakashitaE. (2020)."/>
  <result pre="C.OoiE. E.LinC.-Y.TanH. C.LingA. E.LimB.et al. (2004). Inhibition of SARS Coronavirus" exact="infection" post="in vitro with clinically approved antiviral drugs.Emerg. Infect. Dis.10581â€&quot;586."/>
  <result pre="https://covid19vaccinetrial.co.uk/phase-iiiii-trial-explained(accessed July 1, 2020). ToniatiP.PivaS.CattaliniM.GarrafaE.RegolaF.CastelliF.et al. (2020). Tocilizumab for the" exact="treatment" post="of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute"/>
  <result pre="al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread.Virol. J.2:69. 10.1186/1743-422X-2-6916115318 VuongW.KhanM. B.FischerC.ArutyunovaE.LamerT.ShieldsJ.et al. (2020). Feline"/>
  <result pre="WangY.JiangW.HeQ.WangC.WangB.ZhouP.et al. (2020c). Early, low-dose and short-term application of corticosteroid" exact="treatment" post="in patients with severe COVID-19 pneumonia: single-center experience from"/>
  <result pre="we know.Int. J. Infect. Dis.9444â€&quot;48. 10.1016/j.ijid.2020.03.00432171952 XuX.HanM.LiT.SunW.WangD.FuB.et al. (2020). Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab.Proc. Natl. Acad. Sci."/>
  <result pre="SARS coronavirus and MERS coronavirusâ€&quot;A possible reference for coronavirus disease-19" exact="treatment" post="option.J. Med. Virol.92556â€&quot;563. 10.1002/jmv.25729 n/a., 32104907 YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.et al. (2020b)."/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Clin. Infect."/>
  <result pre="of Mouse Hepatitis Virus.J. Biochem.821103â€&quot;1108. 10.1093/oxfordjournals.jbchem.a131782200604 ZhaL.LiS.PanL.TefsenB.LiY.FrenchN.et al. (2020). Corticosteroid" exact="treatment" post="of patients with coronavirus disease 2019 (COVID-19).Med. J. Aust.212416â€&quot;420."/>
  <result pre="Agents55:105954. 10.1016/j.ijantimicag.2020.10595432234467 ZhangS.LiL.ShenA.ChenY.QiZ. (2020b). Rational use of tocilizumab in the" exact="treatment" post="of novel coronavirus pneumonia.Clin. Drug Investig.261â€&quot;8. 10.1007/s40261-020-00917-332337664 ZhangH.-Z.ZhangH.KemnitzerW.TsengB.CinatlJ.MichaelisM.et al."/>
 </snippets>
</snippetsTree>
